4543 On Other Exchanges
4543 is not on other exchanges.

terumo corp (4543) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TERUMO CORP (4543)

Related News

No related news articles were found.

terumo corp (4543) Related Businessweek News

No Related Businessweek News Found

terumo corp (4543) Details

Terumo Corporation manufactures and sells medical devices and pharmaceuticals worldwide. It provides products in the areas of cardiovascular, hospital, and blood systems. The company offers vascular intervention devices, such as introducer sheathes, guide wires, angiographic catheters, and radial artery compression devices; therapeutic devices; and intravascular imaging systems, including optical frequency domain imaging and intravascular ultrasound systems. It also provides interventional oncology devices, such as micro catheters and guide wires, micro balloon catheters, and drug-elutable beads; cardiopulmonary bypass systems comprising oxygenator with integrated arterial filters, heart-lung machines, and devices for percutaneous cardiopulmonary support system; and thoracic vascular and abdominal vascular grafts. In addition, the company offers infusion systems, including infusion pumps, closed infusion systems, and IV catheters; closed anticancer drug infusion systems; drugs and devices comprising prefilled syringes and pre-fillable syringes; pharmaceuticals and nutritional supplements; and peritoneal dialysis devices. Further, it provides analgesic and antiemetic pain management drugs; diabetes management devices; measuring device systems, such as blood glucose and blood pressure monitors, thermometers, pulse oximeters, and walking intensity and body composition monitors; and basal thermometers, fall prevention products, oral care products, urine test strips, and deodorizing devices. Additionally, the company offers automated blood collection and blood component processing systems, blood bag system with leukocyte reduction filters, pathogen reduction technology systems, centrifugal apheresis systems, cell expansion systems, and autologous cell processing devices. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.

22,441 Employees
Last Reported Date: 06/28/17
Founded in 1921

terumo corp (4543) Top Compensated Officers

Senior Exec. Officer & Director
Total Annual Compensation: ¥141.0M
Compensation as of Fiscal Year 2017.
terumo corp
Cohera Medical, Inc. Announces Exclusive Distribution Agreement with Terumo

Cohera Medical, Inc. announced that it has signed an exclusive, long-term distribution agreement with Terumo Corporation (Tokyo, Japan) for Sylys Surgical Sealant. Under the terms of the distribution agreement, Terumo Corporation (a leading provider of high quality, innovative medical devices), will have the exclusive rights to market Sylys in Japan. The Distribution Agreement provides for license and marketing rights to the Sylys Surgical Sealant product for current and future indications in Japan. This represents a significant market opportunity for both companies as there are nearly a half million colorectal procedures each year collectively in the US and Japan. To date, no other products have been approved for the reduction of colorectal leaks and Sylys is well positioned to fill this unmet medical need.

Phosphagenics Limited Signs Development Agreement with Terumo Corporation

Phosphagenics Limited announced the signing of a development agreement with Terumo Corporation, for the TPM®/Oxymorphone patch in Japan. In January 2017 Phosphagenics and Terumo signed a non-binding term sheet detailing the proposed terms under which Phosphagenics would grant Terumo exclusive rights to develop, market and sell a TPM® enabled Oxymorphone patch in Japan. Since then, both parties have collaborated to finalise the composition of a patch specifically focused on the Japanese market, which prefers a 1-day (24-hour) patch. The success in developing this patch has allowed further progression to a new binding agreement and has also benefited Phosphagenics' 3-day patch, which is designed around the requirements of the US market. The agreement signed targets progression of a 1-day TPM® enabled Oxymorphone patch into the clinic within the first 12 months followed by a formal consultation with Japanese Regulatory Authorities (PMDA) to determine the most efficient way forward to market. Phosphagenics will undertake some of the activities associated with progression of the patch and will receive up to $2 million in development milestone payments through this period. On successful completion of the first Phase 1 study and PMDA consultation, Terumo can activate an exclusive option and progress to a full license agreement. The terms for such an agreement, set out in the previous non-binding term sheet, include Terumo accepting all Japanese development costs, providing additional development and sales milestones, and paying Phosphagenics single to double digit royalties on net sales in Japan. Entry into a license agreement and actual terms remain subject to further agreement by both Parties. Phosphagenics retains full rights to market and/or partner both the 1-day or 3-day TPM®/Oxymorphone patch in any market outside of Japan. As part of this agreement Terumo has now formally informed Phosphagenics of its strategic decision not progress two TPM® enabled patches in parallel. The TPM® enabled Oxycodone patch is therefore free to be partnered by other companies across all territories. The signing of this agreement marks the fourth R&D partnered project between Terumo and Phosphagenics.

Terumo Corporation Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Interim and Year End Dividend Forecast for the Year Ending March 31, 2018; Provides Earnings Guidance for the Half Year Ending September, 2017 and for the Year Ending March 31, 2018

Terumo Corporation reported consolidated earnings results for the first quarter ended June 30, 2017. For the period, the group reported net sales of ¥139,312 million, operating income of ¥23,355 million, ordinary income of ¥22,733 million and profit attributable to owners of parent of ¥16,291 million or ¥43.08 per diluted share compared to net sales of ¥124,519 million, operating income of ¥21,356 million, ordinary income of ¥15,123 million and profit attributable to owners of parent of ¥10,110 million or ¥25.99 per diluted share reported in the same period last year. Income before income taxes was ¥23,435 million against ¥15,079 million reported last year. For the fiscal year ending March 31, 2018, the company reported interim dividend forecast of ¥22.00 per share at the end of the second quarter compared to ¥20.00 per share declared last year. For the fiscal year ending March 31, 2018, the company reported year end dividend forecast of ¥22.00 per share compared to ¥22.00 per share declared last year. For the half year ending September, 2017, the group expected to report net sales of ¥276,000 million, operating income of ¥39,000 million, ordinary income of ¥37,500 million and profit attributable to owners of parent of ¥25,000 million or ¥71.03 per share. For the year ending March 31, 2018, the group expected to report net sales of ¥575,000 million, operating income of ¥82,000 million, ordinary income of ¥79,500 million and profit attributable to owners of parent of ¥53,000 million or ¥150.58 per share.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4543 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4543.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4543 Industry Range
Price/Earnings 28.8x
Price/Sales 3.0x
Price/Book 3.2x
Price/Cash Flow 27.8x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TERUMO CORP, please visit www.terumo.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.